Patents Assigned to Ablynx N.V.
  • Amino acid sequences directed against cellular receptors for viruses and bacteria
    Patent number: 9803018
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Amino acid sequences of the present invention may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 31, 2017
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Dominique Schols, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot, Peter Verheesen
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20170275360
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: —assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: June 6, 2017
    Publication date: September 28, 2017
    Applicant: Ablynx N.V.
    Inventors: JUDITH BAUMEISTER, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20170275361
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: —assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: June 6, 2017
    Publication date: September 28, 2017
    Applicant: Ablynx N. V.
    Inventors: JUDITH BAUMEISTER, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • TNF BINDERS
    Publication number: 20170267752
    Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.
    Type: Application
    Filed: November 14, 2016
    Publication date: September 21, 2017
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
  • Biological materials related to CXCR7
    Patent number: 9758584
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: September 12, 2017
    Assignee: Ablynx N.V.
    Inventors: Francis Descamps, Maria Gonzalez, Pascal Gerard Merchiers, Catelijne Stortelers, Peter Vanlandschoot, Philippe Van Rompaey, Martine Smit, Regorius Leurs, David Andre Baptiste Maussang-Detaille
  • INHIBITION OF BONE RESORPTION WITH RANKL BINDING PEPTIDES
    Publication number: 20170253652
    Abstract: Methods are provided for inhibiting bone resorption and/or osteoclast activity. More specifically, methods are provided wherein polypeptides against RANK-L are administered to a subject less frequently and/or at lower dose, while still maintaining effective inhibition of bone resorption and/or osteoclast activity in the subject at unexpectedly prolonged periods of time, particularly in view of the doses administered.
    Type: Application
    Filed: October 17, 2016
    Publication date: September 7, 2017
    Applicant: Ablynx N.V.
    Inventors: JOSEFIN-BEATE HOLZ, Alex Hemeryck
  • TNF binders
    Patent number: 9745372
    Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: August 29, 2017
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
  • Pulmonary administration of immunoglobulin single variable domains and constructs thereof
    Patent number: 9725522
    Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: August 8, 2017
    Assignee: Ablynx N.V.
    Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
  • METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND USES THEREOF
    Publication number: 20170210822
    Abstract: The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.
    Type: Application
    Filed: June 16, 2015
    Publication date: July 27, 2017
    Applicant: Ablynx N.V.
    Inventor: Christian Duby
  • SERUM ALBUMIN BINDING PROTEINS
    Publication number: 20170210789
    Abstract: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.
    Type: Application
    Filed: January 3, 2017
    Publication date: July 27, 2017
    Applicant: Ablynx N.V.
    Inventors: BRUNO DOMBRECHT, Peter Schotte, Cedric Jozef Neotere Ververken
  • Methods and compositions for the preparation of aerosols
    Patent number: 9713589
    Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: July 25, 2017
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Mauro Sergi, Peter Casteels
  • IMPROVED TNF BINDERS
    Publication number: 20170190769
    Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.
    Type: Application
    Filed: March 13, 2017
    Publication date: July 6, 2017
    Applicant: Ablynx N.V.
    Inventors: MARIE-ANGE Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
  • Biological materials related to c-Met
    Patent number: 9683045
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: June 20, 2017
    Assignee: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
  • AMINO ACID SEQUENCES DIRECTED AGAINST RANK-L AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF BONE DISEASES AND DISORDERS
    Publication number: 20170166647
    Abstract: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: November 21, 2016
    Publication date: June 15, 2017
    Applicant: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Sigrid Cornelis, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
    Patent number: 9670275
    Abstract: The present invention relates to biological materials against HGF and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit binding of HGF to its receptor c-Met.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: June 6, 2017
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Hilde Adi Pierrette Revets, Jo Vercammen, Augustinus Antonius Maria Silvester van Dongen
  • KV1.3 BINDING IMMUNOGLOBULINS
    Publication number: 20170137512
    Abstract: The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kv1.3.
    Type: Application
    Filed: June 18, 2015
    Publication date: May 18, 2017
    Applicant: Ablynx N.V.
    Inventors: Diane Van Hoorick, Erik Depla, Frank Kamiel Delphina Verdonck, Veerle Delanote, Daniel Janssen, Francis Descamps, Mark Edward Labadia, Ann Mikhail, Alisa K. Waterman
  • Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
    Patent number: 9644022
    Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: May 9, 2017
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Catelijne Stortelers
  • IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20170121399
    Abstract: VH domain, in which: (i) the amino acid residue at position 1 12 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 1 10 is one of K or Q; and (iv) in each of cases (i) to (hi), the amino acid at position 1 1 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: May 13, 2015
    Publication date: May 4, 2017
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • STABILIZED SINGLE DOMAIN ANTIBODIES
    Publication number: 20170107302
    Abstract: The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.
    Type: Application
    Filed: June 1, 2016
    Publication date: April 20, 2017
    Applicant: Ablynx N.V.
    Inventors: KAREN SILENCE, Marc Jozef Lauwereys, Torsten Dreier
  • Methods for blocking or reducing binding of interleukin-6 to interleukin-6 receptor
    Patent number: 9617341
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: April 11, 2017
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert